2026 Regional Conference on Biotherapies and Bioproduction in Bourgogne-Franche-Comté
On Wednesday, June 10, 2026, in Dijon, the 2026 Regional Conference on Biotherapies and Bioproduction in Bourgogne-Franche-Comté will take place. This event is supported by the Bourgogne-Franche-Comté Region and the Prefecture of Bourgogne-Franche-Comté, and organized by the Regional Economic Agency of Bourgogne-Franche-Comté.
Launched in spring 2024 by the Bourgogne-Franche-Comté Region with the support of the State, these conferences have brought together regional stakeholders in biotherapies and bioproduction. Together, and after several months of collective work, eight workshops made it possible to identify the region’s strengths and to create a roadmap defining specific guidelines to strengthen the sector at both national and international levels. This ambition, presented during the second edition of the conference in autumn 2024, is to position Bourgogne-Franche-Comté as a leader in the field of innovative therapies and bioproduction. Exchanges with stakeholders highlighted the Region’s enthusiasm and commitment to supporting innovation in healthcare.
Since 2024, numerous actions have been implemented:
- Promotion of the sector within the region, in France, and internationally
- Prospecting and project detection
- Monitoring and coordination of the sector
- Project funding
A brand was also created to highlight the regional momentum: BIOVALIANCE. “With BIOVALIANCE, we carry a vision: that of a region that innovates, produces, and cooperates for the health of tomorrow,” specifies Jérôme DURAIN, President of the Bourgogne-Franche-Comté Region.
This third edition of the regional conference will be an opportunity to review the actions carried out over the past 18 months, those to come, and to discuss stakeholders’ needs in order to continue developing this high-level sector.
See you on Wednesday, June 10 from 9:30 a.m. in Dijon!
To innovate and develop biotechnology and precision medicine, Bourgogne-Franche-Comté benefits from a wide range of expertise throughout the entire value chain, distributed across its territory. Organized around four areas of specialization, these capabilities are mastered by companies with national and international reach in:
- Cell and gene therapies: Établissement Français du Sang and its spin-offs, Carla Biotherapeutics, Urgo (Adhara), Vetoquinol, ABTx…
- Theranostics (therapy and diagnostics): Oncodesign Precision Medicine, Chematech…
- Bioactivators (health tech products and services): RD-Biotech (plasmid DNA), Medix Biochemica and Covalab (antibodies), Biomnigène (sequencing), Smaltis, ICTA…
- Bioproduction processes: Cellquest, Ilsa Group, Cellaven, ARDPI, De Dietrich…